Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- Check2 days agoChange DetectedSite revision updated to v3.5.0, replacing the previous v3.4.3 revision.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded the Ovarian cancer topic and a MedlinePlus Genetics related topic, and updated the revision from v3.4.2 to v3.4.3.SummaryDifference0.2%

- Check23 days agoChange DetectedOvarian cancer and the MedlinePlus Genetics related topic were removed from the page's related topics.SummaryDifference0.1%

- Check37 days agoChange DetectedRevision: v3.4.2 was added and v3.4.1 removed; this is a minor UI revision with no impact on study content, eligibility, enrollment, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check45 days agoChange DetectedRevision: v3.4.1 is now shown, replacing v3.4.0. No study content or eligibility criteria appear to be changed.SummaryDifference0.0%

- Check53 days agoChange DetectedThe changes add a Show glossary option and standardize metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) while removing older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). These updates do not alter core study content, eligibility, or results, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.